Metraipolis › archive › dc_68abde37124c

Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD) — Europe PMC PMID:40941730

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40941730
DOI
10.3390/diagnostics15172243
License (as archived)
solo-consultazione
Archived
2026-11-10T03:15:48.451Z
SHA-256 of the archived text
a69c81e0f954e5a995527081f8ffa30d9e56bbac6dbf1a6e76f760af67fec60c
Stable URL of this page
https://metraipolis.com/documento/dc_68abde37124c

How to cite

Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD) — Europe PMC PMID:40941730 — Europe PMC (en), https://europepmc.org/article/MED/40941730 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_68abde37124c (Metraipolis archive dc_68abde37124c, sha256 a69c81e0f954e5a995527081f8ffa30d9e56bbac6dbf1a6e76f760af67fec60c)
BibTeX
@misc{dc68abde37124c,
  title = {Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD) — Europe PMC PMID:40941730},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40941730},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_68abde37124c; sha256 a69c81e0f954e5a995527081f8ffa30d9e56bbac6dbf1a6e76f760af67fec60c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40941730. Agents can read the archived copy with the MCP tool read_document.